Circassia Pharmaceuticals

    [td_text_with_title custom_title=”Circassia Pharmaceuticals”]Circassia (CIR:LSE) is a specialty biopharmaceutical company focused on the development of novel immunotherapies. These are designed to treat a range of common allergies and autoimmune conditions by controlling patients’ inappropriate immune responses. Our most advanced treatment, Cat-SPIRE, has achieved highly impressive results in clinical studies, and is currently in the final phase of testing for cat allergy.

    Circassia’s pipeline of immunotherapies is based on its unique ToleroMune® technology, and with strong support from its shareholders the Company has made significant progress developing its products following its establishment in 2006. As a private company, we expanded our portfolio of treatments, raised a total of £105 million in investment and successfully completed numerous clinical studies. This progress culminated in a successful initial public offering on the London Stock Exchange on 18 March 2014, and to date the Company has raised over £300 million in investment.  We also continue to maintain strong links with allergy experts, and our joint venture with McMaster University (Hamilton, Canada), Adiga Life Sciences Inc, is pursuing promising new science in the field.

    Circassia’s ultimate ambition is to build a successful financially self-sustaining specialty biopharma company, focused on improving patients’ lives around the world. In the short term, we plan to complete the development and launch of our first allergy treatment, Cat-SPIRE. To achieve this, we are building our commercial capabilities and advancing our phase III program. With the support of our investors, Circassia is making good progress towards meeting its long-term goal.[/td_text_with_title]


    Posts not found

    [td_text_with_title custom_title=”Latest post”]

    Circassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study

    Study on track to report in H1 2016 1,409 subjects randomised; 19% above target Oxford, UK – 8 January 2015: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces that it has completed recruitment into the pivotal phase III study of its cat allergy treatment, Cat-SPIRE.  […]

    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.


    The company was founded by Steve Harris and Charles Swingland in 2006.[2] It was the subject of an Initial Public Offering in March 2014.[3]


    The company's technology, ToleroMune, was initially developed by scientists at Imperial College London.[2] The company is in the process of developing a treatment for cat allergies.[4]


    1. ^ a b c "Accounts for year ended 31 December 2015". Circassia Pharmaceuticals. Retrieved 31 March 2016. 
    2. ^ a b "Fundamentals for Circassia Pharmaceuticals Ord 0.08p". The Telegraph. Retrieved 23 August 2014. 
    3. ^ "Circassia IPO Fuels Optimism on European Biotech". Wall street Journal. 13 March 2014. Retrieved 23 August 2014. 
    4. ^ "Hope of cat allergy cure brings Circassia to stock market". The Telegraph. 6 February 2014. Retrieved 23 August 2014. 

    External links